Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HRH2 | P25021 | 3/20 | 0.44 |
| ▸ | OGA | O60502 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4595357 | 0.85 | SMN1; SMN2 (0.53) | HDAC1HDAC2TSHRALDH1A1GAA | |
| SCHEMBL29057479 | 0.77 | OGA (0.72) | TSHRALDH1A1OGAATM | |
| SCHEMBL5027766 | 0.73 | SMN1; SMN2 (0.46) | HDAC1HDAC2HDAC3HDAC6TSHR | |
| SCHEMBL5025176 | 0.73 | ALDH1A1 (0.48) | HDAC1HDAC2HDAC3GLATSHR | |
| SCHEMBL4015123 | 0.72 | EPHX2 (0.50) | TSHRALDH1A1POLB | |
| SCHEMBL707268 | 0.72 | KMT2A (0.55) | POLBSMN1; SMN2TP53 | |
| SCHEMBL28361719 | 0.72 | TSHR (0.43) | HDAC1HDAC2HDAC3HDAC6TSHR | |
| SCHEMBL5835647 | 0.72 | SMN1; SMN2 (0.49) | HDAC6TSHRALDH1A1HRH2POLB | |
| SCHEMBL29057542 | 0.71 | OGA (0.73) | OGA | |
| SCHEMBL29057427 | 0.71 | OGA (0.77) | ALDH1A1OGAATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948651-A1 | THIAZOLE ANALOGUES AND USES THEREOF | 4SC AG (DE) | 2008-07-30 | — | — | EP | disclosed |
| US-20070149523-A1 | Thiazole Analogues and Uses Thereof | 4SC AG (DE) | 2007-06-28 | — | — | US | disclosed |
| WO-2007054357-A1 | THIAZOLE ANALOGUES AND USES THEREOF | 4SC AG (DE) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149523-A1 | Thiazole Analogues and Uses Thereof | NR3C2, SLC26A4, CLIC4 | HDAC1 461/4885HDAC2 370/4885HDAC3 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.